Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 162   

Articles published

MRK 56.90 -0.39 (-0.68%)
price chart
Merck & Company, Inc. (NYSE:MRK) Analyst Rating Update
Merck & Company, Inc. (NYSE:MRK) shares are expected to touch $66.2 in the short term. This short term price target has been shared by 10 analysts.
Stocks Lure Investment- IAMGOLD Corp. (NYSE:IAG), Merck & Co. Inc. (NYSE ...
Merck & Co. Inc. (NYSE:MRK) released that results from a Phase 3 study examining the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Merck's substance P/neurokinin (NK-1) receptor antagonist, in combination with ...
Merck & Co. Raised to "Strong-Buy" at Vetr Inc. (MRK)
Merck & Co. logo Merck & Co. (NYSE:MRK) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, Market Beat Ratings reports.
Brokerage Firm Ratings Update on Merck & Company, Inc. (NYSE:MRK)  Investor Newswire
Merck & Co. Lifted to Buy at Zacks (MRK)  sleekmoney
Merck & Co., Inc. (MRK) Stock Has Substantial Upside: Barron's
Merck & Co., Inc. (NYSE:MRK), the second-biggest US drug-maker by sales, currently boasts one of the industry's most promising new drug pipelines, according to Barron's.
Large Inflow of Money Witnessed in Merck & Company, Inc.  Insider Trading Report
Momentum Stock Watch: Merck & Company, Inc. (NYSE:MRK)  Enterprise Leader
Merck & Co. Inc. (MRK) Closes 0.63% Down on the Day for June 30
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -0.63% to $56.93, representing a per-share move of $0.36, on volume of 11.53 million shares for Tuesday.
Gilead Sciences Inc. (NASDAQ:GILD) Once Again in Concerns with Merck & Co ...
Gilead Sciences Inc. (NASDAQ:GILD) plummeted over 3.3% on Monday as the U.S. FDA was prosecuted by two advocacy groups looking to force the faster disclosure of clinical examination data that assisted Gilead Sciences Inc win authorization for two ...
Gilead Sciences, Inc. (GILD) Recent Bull Might Not Last Long  Bidness ETC
Pharmaceutical Stocks Including Gilead (NASDAQ:GILD) making their Name in ...  WallStreet.org
Investors Alert: Merck & Co. Inc. (NYSE:MRK), Sunesis Pharmaceuticals, Inc ...
Merck & Co. Inc. (NYSE:MRK) ended the last trading day at $57.29. Company weekly volatility is calculated as 1.33% and price to cash ratio as 10.37.
Stock Report on Merck & Co Inc (NYSE:MRK)
[Business Wire] Merck & Co Inc (NYSE:MRK)(TREND ANALYSIS) known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled ...
TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary ...  Benzinga
Company Update (NYSE:MRK): TECOS, Merck's Cardiovascular Safety Trial of ...  Jutia Group
Gilead Sciences, Inc. (GILD) Says Merck & Co., Inc. Won't Have Same Impact As ...
The next battle in the HCV landscape would be over a pan-genotypic 3-drug combo treatment instead of the drug with the cheaper price tag, said Gilead Sciences, Inc. (NASDAQ:GILD) president and chief operating officer John Milligan. The company said ...
Merck and Co. Inc.'s (NYSE:MRK) entry in the HCV market will not be the ...  WallStreet.org
Hot News: Gilead Sciences Inc. (NASDAQ:GILD St. Jude Medical Inc. (NYSE ...  Stock Transcript
Novo Nordisk A/S, Sanofi SA, Merck & Co Top $62 Billion Diabetes Market In ...
Pfizer Inc. (NYSE:PFE), with global diabetes sales of $7.3 billion, and Eli Lilly, with $4.5 billion in sales, snagged the fourth and fifth spots on the list, respectively.